By proceeding, you agree to our Terms of Use and Privacy Policy.
Key technical assets of TeraImmune 1) Expansion of human regulatory T cells in vitro 2) Receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell)
17-19 May 2022
Turbocharge the Development of Best-In-Class Treg-Directed Therapies, Maximizing Stability and Function to Deliver Safe, Scalable and Efficacious Therapies Globally As Biopharma turn their focus to autoimmune drug development, there has been an explo
Event Ended
USA
Paid
Boston